Biomarin Pharmaceutical Inc. Insider Trading

BMRN

Last 12 months

Insiders sold $4.32M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. EVP, Chief Legal Officer George Eric Davis sold $1.6M on Feb 26, 26% of their stake, outside a plan. The last open-market buy by an executive or director was in Oct 2022.

Net open-market

−$4.32M

0 buys · 5 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Oct 2022

Oct 31, 2022

Get an email when BMRN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 2	George Eric Davis EVP, Chief Legal Officer	SoldNo plan	17,557	$66.28	$1.16M	22%	Form 4
May 7	Gregory R Friberg EVP, Chief R&D Officer	SoldNo plan	3,281	$53.85	177K	6.0%	Form 4
Mar 11	Charles Greg Guyer EVP, Chief Technical Officer	SoldNo plan	16,486	$60.46	997K	17%	Form 4
Feb 26	Gregory R Friberg EVP, Chief R&D Officer	SoldNo plan	6,326	$60.38	382K	14%	Form 4
Feb 26	George Eric Davis EVP, Chief Legal Officer	SoldNo plan	26,061	$61.36	$1.6M	26%	Form 4
May 20, 2025	Erin Burkhart GVP, Chief Accounting Officer	Sold10b5-1 plan	1,786	$59.31	106K	11%	Form 4
May 2, 2025	Cristin Hubbard EVP, Chief Commercial Officer	Sold10b5-1 plan	273	$64.92	18K	0.8%	Form 4
Mar 19, 2025	Erin Burkhart GVP, Chief Accounting Officer	Sold10b5-1 plan	1,295	$71.52	93K	7.1%	Form 4
Mar 6, 2025	Charles Greg Guyer EVP, Chief Technical Officer	SoldNo plan	7,034	$71.28	501K	7.4%	Form 4
Feb 24, 2025	Erin Burkhart GVP, Chief Accounting Officer	Sold10b5-1 plan	1,344	$68.38	92K	9.3%	Form 4
Nov 12, 2024	Charles Greg Guyer EVP, Chief Technical Officer	SoldNo plan	5,278	$66.37	350K	7.1%	Form 4

Sep 2No plan
George Eric Davis
EVP, Chief Legal Officer · sold 17,557 at $66.28
$1.16M
22% of stake
May 7No plan
Gregory R Friberg
EVP, Chief R&D Officer · sold 3,281 at $53.85
177K
6.0% of stake
Mar 11No plan
Charles Greg Guyer
EVP, Chief Technical Officer · sold 16,486 at $60.46
997K
17% of stake
Feb 26No plan
Gregory R Friberg
EVP, Chief R&D Officer · sold 6,326 at $60.38
382K
14% of stake
Feb 26No plan
George Eric Davis
EVP, Chief Legal Officer · sold 26,061 at $61.36
$1.6M
26% of stake
May 20, 202510b5-1 plan
Erin Burkhart
GVP, Chief Accounting Officer · sold 1,786 at $59.31
106K
11% of stake
May 2, 202510b5-1 plan
Cristin Hubbard
EVP, Chief Commercial Officer · sold 273 at $64.92
18K
0.8% of stake
Mar 19, 202510b5-1 plan
Erin Burkhart
GVP, Chief Accounting Officer · sold 1,295 at $71.52
93K
7.1% of stake
Mar 6, 2025No plan
Charles Greg Guyer
EVP, Chief Technical Officer · sold 7,034 at $71.28
501K
7.4% of stake
Feb 24, 202510b5-1 plan
Erin Burkhart
GVP, Chief Accounting Officer · sold 1,344 at $68.38
92K
9.3% of stake
Nov 12, 2024No plan
Charles Greg Guyer
EVP, Chief Technical Officer · sold 5,278 at $66.37
350K
7.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BMRN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with BMRN

CompareIntrinsic value

ALNYAlnylam Pharmaceuticals Inc

$161.08+0.74%81

PRGOPerrigo Company plc

$15.83+0.83%17

UTHRUnited Therapeutics Corporation

$608.49+1.19%78

AMRXAmneal Pharmaceuticals Inc.

$19.95-1.29%57

JAZZJazz Pharmaceuticals plc

$234.66+2.14%58

RPRXRoyalty Pharma plc

$67.56+1.75%19

ELANElanco Animal Health Incorporated

$25.31+3.01%46

SRPTSarepta Therapeutics Inc.

$18.99+2.43%51

Held by ETFs

BMRN is in 154 US ETFs. The largest of them, with BMRN's weight in each:

Spot a number that looks wrong? Check it in BMRN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BMRN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.